News & Events


Join ARMGO at BIO-EUROPE in Leipzig, Germany, October 24 – 26, 2022
10.14.22
ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases
12.20.21
ARMGO Pharma Inc. Announces Clinical Trial of ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies
12.17.19
ARMGO Pharma Receives FDA Orphan Drug Designation for ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies
09.05.18